Published in Cardiovascular Business Week, January 24th, 2006
The recent contracts brought the total for the fourth quarter to $31.7 million to date. Five of the contracts are for Through QT studies totaling approximately $6.2 million from two pharmaceutical companies, a biotechnology organization, the U.S. operation of a major Japanese pharmaceutical company, and an emerging U.S. drug developer. This brings the number of Thorough QT...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.